|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01099 SINOPHARM
Nominal 
19.010 +0.240 (+1.279%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 286,042,998 | -2.946% | 584,507,930 | 596,569,565 | 552,147,550 | 521,051,235 |
| Cost of Sales | (265,696,092) | -2.598% | (540,252,540) | (548,057,887) | (504,713,490) | (477,000,627) |
| Gross Profit | 20,346,906 | -7.275% | 44,255,390 | 48,511,678 | 47,434,060 | 44,050,608 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | (598,478) | |
| Profit / (Loss) on Disposal | -- | -- | (1,582,079) | (2,067,764) | (1,936,170) | (1,130,821) | |
| Other Non-operating Items | 71,728 | -- | (1,058,658) | 625,967 | 82,278 | (375,813) | |
| Share of Results of Asso. & JCEs | 687,853 | 10.106% | 1,199,396 | 1,107,349 | 1,067,067 | 1,069,868 | |
| Profit / (Loss) before Taxation | 7,209,893 | -5.089% | 14,000,899 | 19,512,137 | 18,563,819 | 17,003,162 | |
| Taxation | (1,872,648) | 10.333% | (3,577,305) | (4,502,309) | (4,218,377) | (3,938,389) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (1,871,559) | -14.749% | (3,373,911) | (5,956,068) | (5,819,787) | (5,306,127) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,465,686 | -6.431% | 7,049,683 | 9,053,760 | 8,525,655 | 7,758,646 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 995,377 | -7.309% | 2,328,242 | 2,430,374 | 3,189,992 | 3,402,869 |
| Depreciation & Amortisation | 2,233,389 | -3.948% | 4,733,692 | 4,430,248 | 4,165,019 | 3,922,058 |
| Directors' Emoluments | -- | -- | 7,273 | 14,991 | 14,516 | 15,277 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 111.000 | -6.723% | 226.000 | 290.000 | 273.000 | 249.000 |
| DPS (cts) | 0.000 | -- | 68.000 | 87.000 | 82.000 | 75.000 |
| Dividend Payout Ratio (%) | -- | -- | 30.088% | 30.000% | 30.037% | 30.120% |
| Cash flow per share ($) | -- | -- | 3.704 | 5.510 | 6.726 | 2.983 |
| NBV per share ($) | 25.710 | -- | 25.278 | 23.900 | 21.812 | 19.831 |
| Remarks: | Real time quote last updated: 11/09/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,465,686 |
| %Change | -6.431% |
| EPS / (LPS) | RMB 1.110 |
| NBV Per Share (¥) | RMB 25.710 |